본문으로 건너뛰기
← 뒤로

Performance of a Screening Mammography AI Algorithm Repurposed for Symptomatic Mammography in a Tertiary Outpatient Clinic.

Diagnostics (Basel, Switzerland) 2026 Vol.16(7)

Ngo H, Niller E, Schmitz E, Kotter E, Windfuhr-Blum M, Neubauer C, Palacios AL, Bamberg F, Neubauer J, Weiss J, Wilpert C

📝 환자 설명용 한 줄

: The aim of the study was to evaluate the diagnostic accuracy of a commercial artificial intelligence (AI) algorithm originally developed for screening mammography when applied to symptomatic women p

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 95% CI 0.86-1.00

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Ngo H, Niller E, et al. (2026). Performance of a Screening Mammography AI Algorithm Repurposed for Symptomatic Mammography in a Tertiary Outpatient Clinic.. Diagnostics (Basel, Switzerland), 16(7). https://doi.org/10.3390/diagnostics16070984
MLA Ngo H, et al.. "Performance of a Screening Mammography AI Algorithm Repurposed for Symptomatic Mammography in a Tertiary Outpatient Clinic.." Diagnostics (Basel, Switzerland), vol. 16, no. 7, 2026.
PMID 41975698

Abstract

: The aim of the study was to evaluate the diagnostic accuracy of a commercial artificial intelligence (AI) algorithm originally developed for screening mammography when applied to symptomatic women presenting to a tertiary outpatient clinic. : This single-center, retrospective diagnostic accuracy study included women who presented with breast symptoms to a tertiary outpatient clinic between January and June 2013 and underwent digital mammography. An AI algorithm cleared by the U.S. Food and Drug Administration (FDA)-cleared AI algorithm was applied to all mammograms and generated continuous malignancy scores ranging from 1 to 100. Mammographic breast density was classified according to the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) by two experienced radiologists. Histopathology, when available, or otherwise a minimum of 2 years of clinical and imaging follow-up served as the reference standard. Diagnostic performance was assessed using receiver operating characteristic (ROC) analysis with calculation of the area under the curve (AUC) and 95% confidence intervals (CI) derived by patient level bootstrap resampling ( = 2000). Analyses were performed for the overall cohort and stratified by breast density (non-dense [BI-RADS A-B] vs. dense [BI-RADS C-D]). : A total of 78 women (mean age, 55 ± 11 years) were included, of whom 16 had histopathological verification of suspicious lesions with proven breast cancer in 14 patients and 62 were classified based on follow-up alone. In the overall cohort (156 breasts, including 15 breasts with malignancies), the AI algorithm achieved an AUC of 0.96 (95% CI: 0.86-1.00). Performance remained high in non-dense breasts (AUC = 0.96; 95% CI: 0.88-1.00) and dense breasts (AUC = 0.99; 95% CI: 0.93-1.00), with no statistically significant difference observed between density subgroups (DeLong test, = 0.36), although subgroup comparisons were underpowered. Decision curve analysis suggested a consistent positive net benefit across a wide range of threshold probabilities in both density groups. : In this preliminary, single-center retrospective cohort, a screening-trained AI algorithm showed promising diagnostic accuracy when applied to symptomatic mammograms. These findings require validation in larger, contemporary, multicenter cohorts before clinical implementation.